⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19415973 | 1.00 | — | — | |
| SCHEMBL20369817 | 1.00 | — | — | |
| SCHEMBL12568357 | 0.79 | — | — | |
| SCHEMBL20980675 | 0.79 | — | — | |
| SCHEMBL10261275 | 0.79 | — | — | |
| SCHEMBL13282283 | 0.79 | — | — | |
| SCHEMBL24611315 | 0.77 | POLB (0.31) | — | |
| SCHEMBL18949753 | 0.77 | — | — | |
| SCHEMBL19501980 | 0.77 | — | — | |
| SCHEMBL19415967 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-11-23 | — | — | US | disclosed |
| US-20230372536-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-11-23 | — | — | US | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180193264-A1 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-07-12 | — | — | US | disclosed |
| US-9957299-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9937126-B2 | Wnt compositions and methods for purification | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170369871-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. | 2017-12-28 | — | — | US | disclosed |
| US-8859723-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859723-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210743-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210743-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |